myClin Selected For Unprecedented Collaborative Clinical Trial By The Leukemia & Lymphoma Society (LLS)
myClin will be utilized to connect thirteen organizations in a first-ever collaborative clinical trial to treat Acute Myeloid Leukemia (AML), a form of cancer affecting 20,000 americans annually.
Philadelphia, PA – October 26, 2016. myClin was selected for a groundbreaking Acute Myeloid Leukemia (AML) clinical trial sponsored by the Leukemia & Lymphoma Society (LLS). Starting initially with 13 organizations and institutions, they will be collaborating on the myClin Clinical Trial Knowledge Platform, with the support and guidance of the U.S Food & Drug Administration (FDA). myClin offers a transformative collaboration channel for drug development teams, streamlining communication and allowing for a robust, data-driven clinical trial oversight.
myClin will allow the LLS Research team to coordinate with five leading cancer centers, the Clinical Research Organization (CRO) INC Research, the genomics company Foundation Medicine, and the biopharmaceutical companies Alexion, Boehringer Ingelheim, Celgene, and Gilead. Additional drug development companies and clinical sites will join the clinical study as it unfolds.
“We developed the myClin platform to better connect clinical sites, CROs, and sponsors, and help them achieve a greater level of compliance” explains James Denmark, CEO & Founder at myClin. “We’re very proud to facilitate such an innovative clinical study along with prestigious organizations.”
The clinical study team, sponsors, and oncology experts will exchange, review, and comment on study documents in myClin’s central, secure, and private environment. Entitled “Beat AML Master Trial”, this study is among the first cancer clinical trials to be led by a nonprofit health organization and relies on an innovative Precision Medicine protocol. The trial is designed to speed up the process of finding better treatments for AML.
The team will receive a considerable amount of input from multiple organizations and myClin will allow for simultaneous and collaborative reviews. myClin will facilitate the study conduct by bringing new team members up to speed rapidly, and by keeping participating organizations engaged and connected at all times. myClin will simultaneously allow for an auto-documented, data-driven clinical trial oversight for the Leukemia & Lymphoma Society and the FDA who is advising and guiding the LLS on this project.
myClin is the leading Clinical Trial Knowledge Platform, offering a transformative collaboration channel and the most documented, data-driven clinical trial oversight. The company’s mission is to leverage technology to enhance participation, engagement, collaboration, and compliance in clinical trials. The team of clinical research veterans that created myClin in 2008 brought deep experience delivering clinical operations services and building feature-rich eClinical systems. Since then, myClin has been used across all phases of research, in global bio-pharmaceutical and device studies with thousands of clinical users. myClin is headquartered in Philadelphia, PA, with offices in San Francisco, CA, and the UK. Watch a demo of myClin at myclin.com/demo
CEO & Founder, myClin
+1 (877) 211-8297